Systemic Adjuvant Therapy in Early HER2+ Breast Cancer: Escalating w/New HER2 Targeted Tx (Neratinib, Pertuzumab, T-DMI1), and When to De-Escalate?
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Cagatay Arslan
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Cagatay Arslan
Comments 0
Login to view comments.
Click here to Login